NYSE - Nasdaq Real Time Price • USD
Pfizer Inc. (PFE)
At close: May 7 at 4:00 PM EDT
After hours: May 7 at 7:59 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 15 | 15 | 15 | 15 |
| Avg. Estimate | 0.45 | 0.55 | 2.37 | 2.77 |
| Low Estimate | 0.3 | 0.41 | 2.15 | 2.45 |
| High Estimate | 0.59 | 0.67 | 2.63 | 3.13 |
| Year Ago EPS | 0.67 | -0.17 | 1.84 | 2.37 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 13 | 12 | 16 | 16 |
| Avg. Estimate | 13.05B | 14.89B | 60.53B | 62.87B |
| Low Estimate | 12.05B | 13.35B | 58.21B | 60.86B |
| High Estimate | 13.99B | 16.02B | 62.26B | 64.5B |
| Year Ago Sales | 12.73B | 13.23B | 58.5B | 60.53B |
| Sales Growth (year/est) | 2.50% | 12.50% | 3.50% | 3.90% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 0.57 | -0.34 | -0.22 | 0.52 |
| EPS Actual | 0.67 | -0.17 | 0.1 | 0.82 |
| Difference | 0.1 | 0.17 | 0.32 | 0.3 |
| Surprise % | 17.50% | 50.00% | 145.50% | 57.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.45 | 0.55 | 2.37 | 2.77 |
| 7 Days Ago | 0.44 | 0.58 | 2.21 | 2.73 |
| 30 Days Ago | 0.46 | 0.58 | 2.2 | 2.76 |
| 60 Days Ago | 0.45 | 0.57 | 2.2 | 2.74 |
| 90 Days Ago | 0.42 | 0.54 | 2.05 | 2.53 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | 2 | -- |
| Up Last 30 Days | 6 | 3 | 14 | 7 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 2 | 1 | -- | 1 |
Growth Estimates
| CURRENCY IN USD | PFE | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -32.80% | -- | -- | 7.00% |
| Next Qtr. | 423.50% | -- | -- | 10.70% |
| Current Year | 28.80% | -- | -- | 4.50% |
| Next Year | 16.90% | -- | -- | 13.20% |
| Next 5 Years (per annum) | -1.33% | -- | -- | 10.91% |
| Past 5 Years (per annum) | -1.53% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 5/2/2024 |
| Reiterates | BMO Capital: Outperform to Outperform | 5/2/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/18/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/15/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/5/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/1/2024 |
Related Tickers
LLY Eli Lilly and Company
777.77
+1.45%
AMGN Amgen Inc.
300.30
+0.27%
JNJ Johnson & Johnson
148.72
+0.09%
BMY Bristol-Myers Squibb Company
44.04
+0.32%
ABBV AbbVie Inc.
162.55
-0.11%
MRK Merck & Co., Inc.
130.38
+2.20%
GILD Gilead Sciences, Inc.
65.46
-0.12%
GSK GSK plc
44.15
+1.61%
AZN AstraZeneca PLC
76.32
+0.74%
BIIB Biogen Inc.
218.92
-1.13%